I lost six stone on Mounjaro – people are stunned by my waistline but I had 3 gross side effects people DON'T talk about
A WOMAN has revealed that she lost six stone in seven months while using Mounjaro, but noticed some very strange side effects that people don't talk about.
Mia Melville, a young woman from the UK, once topped the scales at 18 stone 3 lbs, but was able to slim down thanks to weight loss injections.
3
Not only did Mia experience a long list of side effects, including egg-tasting sulfur burps, but experts and NHS medics have now shared a stern warning about the dangers of taking such medications without a prescription.
Sun GP Dr Zoe Williams acknowledged that Mounjaro, which could soon be rolled out on the NHS, can save the lives of people with 'life-threatening levels of obesity.'
But despite this, the NHS warned: 'Never take an anti-obesity medicine if it has not been prescribed to you.
"These types of medicines may not be safe for you and can cause serious side effects.'
About half a million Brits use weight loss drugs - and the number is expected to double in the next year.
Mounjaro works by suppressing your appetite, making people feel fuller for longer.
The injections are licensed for patients with type 2 diabetes and to assist those who are clinically obese (with a Body Mass Index of 30 or over).
One jab is administered each week but the duration is dependent on someone's weight.
Mia took to social media to share a close-up look at her impressive weight loss transformation, which was thanks to the jabs, leaving many open-mouthed.
At the start of Mia's short clip, we saw her on holiday as she sat on a sun lounger in a white swimsuit.
Weight Loss Jabs - Pros vs Cons
Covering her face, Mia wrote: 'Some days I feel I haven't lost any weight.'
But seconds later, Mia shared a short clip of her new frame, where she posed in a tight black top showing off her slimmed down physique.
The gorgeous woman confirmed that she lost six stone thanks to the fat jabs and has two stone left to lose to reach her goal weight.
Alongside using Mounjaro, which is regarded by some as the King Kong of weight loss jabs, Mia tried her best to eat healthily and focused on a high protein diet.
Having said that, the foodie stressed that she 'didn't restrict' herself and still ate takeaways and chocolate.
Everything you need to know about fat jabs
Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases.
Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK.
Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market.
Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year.
How do they work?
The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight.
They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists.
They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high.
Can I get them?
NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.
Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure.
GPs generally do not prescribe the drugs for weight loss.
Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk.
Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health.
Are there any risks?
Yes – side effects are common but most are relatively mild.
Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea.
Dr Sarah Jarvis, GP and clinical consultant at patient.info, said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.'
Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia.
Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health.
Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
Mia's grim side effects and handy tips
In a follow-up clip, Mia shared her tips for those also taking Mounjaro - plus the grim side effects she battled.
She stressed that taking daily vitamins is vital, as your body may not be getting the essential nutrients it needs due to appetite suppression.
Mia also explained the importance of staying hydrated and advised that drinking two to three litres of water a day is crucial for managing side effects.
The content creator shared that she injected with her weekly dose in the evenings as she found this helped with potential side effects.
While many associate headaches, nausea and constipation with Mounjaro, Mia revealed some of the gross side effects she experienced that people don't talk about - which include sulfur burps, vomiting and diarrhoea.
Four weeks into using the fat jabs, Mia dealt with nausea, headaches, constipation and sulfur burps - also known as rotten egg burps - which are burps that have a foul, unpleasant smell similar to that of rotten eggs.
What are the other side effects of weight loss jabs?
Like any medication, weight loss jabs can have side effects.
Common side effects of injections such as Ozempic include:
Nausea: This is the most commonly reported side effect, especially when first starting the medication. It often decreases over time as your body adjusts.
Vomiting: Can occur, often in conjunction with nausea.
Diarrhea: Some people experience gastrointestinal upset.
Constipation: Some individuals may also experience constipation.
Stomach pain or discomfort: Some people may experience abdominal pain or discomfort.
Reduced appetite: This is often a desired effect for people using Ozempic for weight loss.
Indigestion: Can cause a feeling of bloating or discomfort after eating.
Serious side effects can also include:
Pancreatitis: In rare cases, Ozempic may increase the risk of inflammation of the pancreas, known as pancreatitis, which can cause severe stomach pain, nausea, and vomiting.
Kidney problems: There have been reports of kidney issues, including kidney failure, though this is uncommon.
Thyroid tumors: There's a potential increased risk of thyroid cancer, although this risk is based on animal studies. It is not confirmed in humans, but people with a history of thyroid cancer should avoid Ozempic.
Vision problems: Rapid changes in blood sugar levels may affect vision, and some people have reported blurry vision when taking Ozempic.
Hypoglycemia (low blood sugar): Especially if used with other medications like sulfonylureas or insulin.
Mia advised those dealing with sulfur burps to take peppermint oil capsules, which you can purchase from Holland & Barrett.
12 weeks in, she was not only dealing with nausea, but also experienced vomiting and diarrhoea too.
Mia also recommended those using Mounjaro to not move up a dose every four weeks unless it is necessary.
Social media users react
The TikTok clip, which was posted under the username @ miamelville, has clearly left many open-mouthed, as it has quickly racked up 68,200 views.
It also amassed 2,111 likes and 171 comments, as many eagerly rushed to praise her jaw-dropping glow up.
One person said: 'You look amazing.'
Another added: 'Absolutely incredible. Well done you!'
A third commented: 'Wow amazing results. You're looking fabulous!'
Not only this, but at the same time, someone else penned: 'Oh my goodness Mia! Look at that waistline.'
'Potential to kill'
Although many were impressed with Mia's weight loss, users should note that Mounjaro can have fatal consequences.
The drugs can be lawfully supplied when prescribed by a practitioner - such as a doctor, nurse or a pharmacist-independent prescriber.
But increasingly, people have been buying them through online pharmacies with insufficient checks.
Only recently, figures from the Medicines and Healthcare products Regulatory Agency revealed fat jabs had been linked to 82 deaths across the UK.
calling for a probe into the jab's "potential to kill."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
40 minutes ago
- Daily Mirror
Tesco shoppers warned after supermarket puts new label on popular product
The NHS has issued a stark warning to Tesco shoppers who buy the supermarket's own-brand toilet roll, urging them to 'keep an eye out' and 'contact your GP practice if something doesn't feel right' The NHS is calling on Tesco customers to 'keep an eye out' and to 'contact your GP practice if something doesn't feel right', issuing a stark health warning as Tesco's exclusive Luxury Soft loo rolls now sport the NHS logo on their wrapping. In a bid to ramp up bowel cancer awareness, the partnership between NHS and Britain's leading grocer aims to tap into the regular shopping habits of consumers. Echoing across social media platform X, the NHS broadcasted: "Keep an eye out for our logo on @Tesco toilet roll-78.9 million rolls sold and counting!" The move acts as a timely nudge for shoppers to stay vigilant for early signs of cancer during their bathroom routine. READ MORE: 'I'm a fashion editor and found an unlikely retailer selling glitzy festival-ready outfits' The NHS is highlighting: "It's a reminder for people to look out for possible signs of cancer when going to the loo. Know what's normal for you and contact your GP practice if something doesn't feel right." On each pack, just below the NHS logo, is a critical message which reads: "Finding cancer earlier makes it more treatable and can save lives." On this unique packaging, customers will find a checklist of cancer indicators that might be detected in the loo, including changes in bowel movements or blood traces, reports the Express. For an exhaustive list of cancer symptoms, individuals are encouraged to navigate to Signs of bowel cancer include: changes in your poo, such as having softer poo, diarrhoea or constipation that is not usual for you needing to poo more or less often than usual for you blood in your poo, which may look red or black bleeding from your bottom often feeling like you need to poo, even if you've just been to the toilet tummy pain a lump in your tummy bloating losing weight without trying feeling very tired or short of breath – these are signs of anaemia, which can be caused by bowel cancer Should anyone experience symptoms of bowel cancer for more than three weeks, it's imperative to consult a doctor. The NHS offers comfort, stating: "Try not to be embarrassed. The doctor or nurse will be used to talking about these symptoms." If you observe that your stools are black or dark red, or if you're suffering from bloody diarrhoea, it's essential to arrange an urgent GP appointment or seek help from NHS 111. Assistance can be accessed by dialling 111 or using the online service at Cancer manifests in over 200 different varieties and can impact any part of the body, including organs, blood, bone marrow, and the immune system. In some cases, cancer may spread from its original location to other areas of the body, a process referred to as secondary cancer or metastasis. The specific type of cancer dictates the treatment approach. Standard treatments for cancer include surgical removal of the tumour, chemotherapy with drugs designed to eradicate cancer cells, and radiotherapy which employs radiation to target and eliminate cancer cells. Additional treatment methods might encompass immunotherapy, enhancing the immune system's ability to combat cancer, and hormone therapy, aimed at decelerating or stopping the proliferation of cancerous cells. The NHS reassures patients: "You'll be looked after by a team of specialists who will work with you to create a treatment plan that is best for you."
The Independent
an hour ago
- The Independent
More testing needed for genetic cancer risk as too many women ‘missed', experts say
A new study has revealed that families of some cancer patients are being denied the opportunity to learn about their potential cancer risk due to inconsistencies in genetic testing. Academics have warned that the absence of adequate testing for Lynch syndrome is leaving some cancer patients unaware of their risk of developing other cancers. Lynch syndrome, a rare hereditary condition, elevates the risk of cancers of the bowel, womb, and ovaries. It arises from a gene mutation affecting DNA error correction during replication, potentially leading to uncontrolled cell growth. NHS guidelines stipulate that patients with bowel or womb cancer should undergo tumour assessments for Lynch syndrome markers. The identification of these markers should prompt a referral for genetic testing, confirming the diagnosis and enabling access to support and guidance regarding cancer risks for both the patients and their families. A new study by academics at the University of Edinburgh found not all womb cancer patients are being sent for genetic testing. Researchers examined data on 2,500 womb cancer patients across the UK and Ireland between 2022 and 2023. They found that 91 per cent of tumours were tested for markers of Lynch syndrome, but the test results were not routinely communicated to the wider clinical team. This means that follow-up genetic counselling and blood tests were not always arranged. Of the 181 participants eligible for genetic counselling, just under two-thirds (64 per cent) were referred for appointments, according to the study, which has been published in the journal BMJ Oncology. Researchers said those who were referred faced long waits, resulting in high dropout rates, meaning only 48 per cent of those eligible went on to get the test. Experts from the university said gaps in testing mean some womb cancer patients with Lynch syndrome go undetected. Family members are also left vulnerable to cancer risk, unaware they may have the condition. Dr Neil Ryan, from the University of Edinburgh, who leads the UK audit and research collaborative in obstetrics and gynaecology, said: 'Despite clear guidance and excellent rates of tumour testing, too many women with Lynch syndrome are still being missed because they're not referred for definitive blood testing in a timely way. 'This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected. 'Tumour testing is only cost-effective if it leads to diagnosis — we urgently need to make mainstream testing truly mainstream.'
Daily Mail
an hour ago
- Daily Mail
Bombshell research shows weight-loss drugs like Ozempic don't work as well as companies boasted
Blockbuster weight loss drugs like Ozempic might not work as well as advertised, a bombshell study reveals. A Cleveland Clinic study found patients taking semaglutide and tirzepatide - the active ingredients in Ozempic, Wegovy and Mounjaro - lost up to 50 percent less weight than what drug companies reported in clinical trials. They were also 40 percent more likely to go off the drugs within a year than patients in trials for reasons such as side effects being too severe. In the new study, researchers looked at nearly 8,000 obese Americans who were prescribed either semaglutide or tirzepatide for a year. One in five stopped taking the drugs within three months and nearly one in three stopped before the end of the year. Patients in the new study lost anywhere from four to 12 percent of their body weight in a year depending on how long they stayed on the drugs. But in the drugs' clinical trials, they lost between 15 and 21 percent of their weight. The researchers said the disparity could be due to higher rates of patients stopping the drugs and patients using lower doses than those in clinical trials. Patients also complained of high drug costs and harsh side effects, which have included stomach paralysis and blindness in severe cases. Dr Hamlet Gasoyan, lead study author and researcher at Cleveland Clinic's Center for Value-Based Care, said: 'Our study shows that patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trials. 'According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomized clinical trial settings.' About one in eight Americans report taking a GLP-1 agonist like Ozempic or Wegovy at some point in their lives. And recent research shows their popularity has soared 600 percent since 2019. The study, published Tuesday in Obesity Journal, looked at 7,881 adults patients obese patients using electronic health data. The majority (6,109) received semaglutide while the remainder took tirzepatide. It's unclear if they took specific brand names like Ozempic or Wegovy. The average participant age was 51 and three in four patients were women. Their average body mass index (BMI) was 39, which is considered 'severe obesity.' Any BMI over 30 is obese. Of those patients, 1,320 had prediabetes, a precursor to type 2 diabetes that affects 100million Americans, most of whom don't know they have it. Participants began taking semaglutide or tirzepatide for obesity between 2021 and 2023. Those that stopped taking the drugs within three months were considered 'early' discontinuers and those who stopped in three to 12 months were 'late' discontinuers. Researchers found about 20 percent of participants stopped taking the GLP-1 drugs early and 32 percent stopped late. Additionally, 80 percent were on lower maintenance doses than when they started. This was the equivalent of 1 mg or less of semaglutide or less than 7.5 mg of tirzepatide. A maintenence dose is the amount needed to sustain weight loss. After one year, people who stopped taking the drug early had a four percent weight reduction compared to seven percent for those who stopped late. The above graph shows weight reductions in patients who stopped taking weight loss drugs within three months, in three to 12 months and who never stopped Those who stayed on the drugs for the full year lost 12 percent, and participants who kept with the drugs and took higher maintenance dosages lost 14 percent body weight on semaglutide and 18 percent on tirzepatide. In semaglutide and tirzepatide's clinical trials, patients lost between 15 and 21 percent of their weight after one year, up to 50 percent less than those in the new study who stayed on the drugs for a year. The researchers believe participants lost less weight than those in clinical trials promoted by drug companies because they were more likely to stop taking the drugs, hampering their progress. They cited clinical trials showing patients discontinued the drugs at a rate of 17 percent, up to 40 percent less often. Patients in clinical trials were also more likely to take higher doses. Dr Gasoyan said: 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions.' The team found patients most commonly stopped taking weight loss drugs due to high costs, issues with insurance coverage, risk of side effects and medication shortages.
